MX2022002877A - Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. - Google Patents

Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.

Info

Publication number
MX2022002877A
MX2022002877A MX2022002877A MX2022002877A MX2022002877A MX 2022002877 A MX2022002877 A MX 2022002877A MX 2022002877 A MX2022002877 A MX 2022002877A MX 2022002877 A MX2022002877 A MX 2022002877A MX 2022002877 A MX2022002877 A MX 2022002877A
Authority
MX
Mexico
Prior art keywords
hpk1
hpk1 antagonists
antagonists
inhibition
compositions
Prior art date
Application number
MX2022002877A
Other languages
English (en)
Inventor
Ian Linney
Alexandre Cote
Stuart Ward
Jeremy Robert Greenwood
Grant Wishart
Neelu Kaila
Ben Whittaker
Abba Leffler
Daniel L Severance
Steven K Albanese
Original Assignee
Nimbus Saturn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Saturn Inc filed Critical Nimbus Saturn Inc
Publication of MX2022002877A publication Critical patent/MX2022002877A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invención proporciona compuestos, sus composiciones, y métodos de uso de los mismos para la inhibición de HPK1, y el tratamiento de trastornos mediados por HPK1.
MX2022002877A 2019-09-13 2020-09-11 Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. MX2022002877A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900152P 2019-09-13 2019-09-13
US202063032070P 2020-05-29 2020-05-29
PCT/US2020/050524 WO2021050964A1 (en) 2019-09-13 2020-09-11 Hpk1 antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2022002877A true MX2022002877A (es) 2022-08-08

Family

ID=74866704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002877A MX2022002877A (es) 2019-09-13 2020-09-11 Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.

Country Status (13)

Country Link
US (7) US20210078996A1 (es)
EP (1) EP4027995A4 (es)
JP (1) JP2022547719A (es)
KR (1) KR20220105631A (es)
CN (1) CN114945366A (es)
AU (1) AU2020347274A1 (es)
BR (1) BR112022004451A2 (es)
CA (1) CA3150108A1 (es)
CO (1) CO2022002759A2 (es)
IL (1) IL291244A (es)
MX (1) MX2022002877A (es)
TW (1) TW202126647A (es)
WO (1) WO2021050964A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
MX2022002877A (es) * 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
PE20230323A1 (es) 2020-05-01 2023-02-22 Pfizer Compuestos de azalactama como inhibidores de hpk1
CN112047942B (zh) * 2020-10-26 2022-01-18 都创(上海)医药科技股份有限公司 一种7-氟咪唑并[1,2-a]吡啶的合成方法
US20230096641A1 (en) * 2021-02-12 2023-03-30 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4301756A1 (en) 2021-03-05 2024-01-10 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2024513011A (ja) * 2021-03-29 2024-03-21 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション Ｎ－（（ｒ）－１－（３－クロロピリジン－２－イル）－２，２，２－トリフルオロエチル）－２－（（ｓ）－２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－カルボキサミドによる治療方法
CN115611925A (zh) * 2021-07-14 2023-01-17 轩竹生物科技股份有限公司 Hpk1抑制剂及其用途
CN117693503A (zh) 2021-07-20 2024-03-12 阿斯利康(瑞典)有限公司 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
WO2023015199A1 (en) * 2021-08-03 2023-02-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN114230514A (zh) * 2021-11-26 2022-03-25 渭南瑞联制药有限责任公司 一种合成3-氟-2-氨基异烟腈的方法
WO2023160577A1 (zh) * 2022-02-23 2023-08-31 正大天晴药业集团股份有限公司 含有吡咯啉酮的稠合双环化合物
WO2023193759A1 (en) * 2022-04-07 2023-10-12 Insilico Medicine Ip Limited Hpk1 antagonists and uses thereof
WO2023208127A1 (zh) * 2022-04-27 2023-11-02 南京明德新药研发有限公司 杂芳基取代的双环化合物及其应用
WO2023237085A1 (zh) * 2022-06-10 2023-12-14 贝达药业股份有限公司 Hpk1抑制剂及其在医药上的应用
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
CN114940683B (zh) * 2022-07-26 2023-01-17 轩竹(北京)医药科技有限公司 Hpk1抑制剂及其用途
WO2024078448A1 (zh) * 2022-10-10 2024-04-18 珠海宇繁生物科技有限责任公司 一种hpk1激酶抑制剂及其制备方法和应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2475569A (en) * 1944-02-07 1949-07-05 American Cyanamid Co Substituted pyridine compound
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
EE05351B1 (et) 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
CA2445395C (en) 2001-04-27 2010-03-30 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent comprising the same as effective component
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
SI1536827T1 (sl) 2002-08-14 2009-06-30 Silence Therapeutics Ag Uporaba protein-kinaze n beta
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
KR101168441B1 (ko) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
AU2004257167B2 (en) 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
PL3153514T3 (pl) 2004-05-13 2022-01-10 Icos Corporation Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
KR20080011199A (ko) * 2005-04-19 2008-01-31 교와 핫꼬 고교 가부시끼가이샤 질소 함유 복소환 화합물
CN101175738B (zh) 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
DK1931645T3 (da) 2005-10-07 2014-09-29 Exelixis Inc N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
DE602007007323D1 (de) 2006-04-26 2010-08-05 Hoffmann La Roche Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
EA017218B1 (ru) 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
TWI713942B (zh) 2010-05-04 2020-12-21 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
NO2694640T3 (es) 2011-04-15 2018-03-17
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2013086397A1 (en) 2011-12-08 2013-06-13 Array Biopharma Inc. Urea compounds as gka activators
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2871445C (en) 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SI3495358T1 (sl) 2012-11-08 2022-06-30 Bristol-Myers Squibb Company z amidi substituirane heterociklične spojine, uporabne kot modulatorji IL-12, IL-23 in/ali IFN alfa odzivov
MX2015005272A (es) 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
JP6526065B2 (ja) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
KR101660863B1 (ko) * 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
KR101846475B1 (ko) * 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
LT3322711T (lt) * 2015-06-25 2021-05-10 University Health Network Hpk1 inhibitoriai ir jų panaudojimo būdai
WO2017123884A1 (en) 2016-01-15 2017-07-20 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2017147328A1 (en) * 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
TW201811799A (zh) * 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
US10377743B2 (en) * 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
JP7025426B2 (ja) * 2016-11-30 2022-02-24 アリアド ファーマシューティカルズ， インコーポレイテッド 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ
PT3555064T (pt) 2016-12-16 2023-01-20 Pfizer Agonistas dos receptores glp-1 e suas utilizações
TW201904964A (zh) * 2017-03-30 2019-02-01 瑞士商赫孚孟拉羅股份公司 作為ｈｐｋ1之抑制劑的啶
CN109721620B (zh) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
US11166959B2 (en) * 2017-11-06 2021-11-09 Bristol-Myers Squibb Company Isofuranone compounds useful as HPK1 inhibitors
US10745388B2 (en) * 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) * 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US20200038378A1 (en) 2018-04-01 2020-02-06 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2020089026A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
MX2022002877A (es) * 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
US11731953B2 (en) * 2020-06-22 2023-08-22 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Also Published As

Publication number Publication date
US11021481B2 (en) 2021-06-01
TW202126647A (zh) 2021-07-16
US20210078998A1 (en) 2021-03-18
US20240025898A1 (en) 2024-01-25
EP4027995A4 (en) 2023-08-23
US20210078996A1 (en) 2021-03-18
JP2022547719A (ja) 2022-11-15
KR20220105631A (ko) 2022-07-27
CA3150108A1 (en) 2021-03-18
AU2020347274A1 (en) 2022-03-31
BR112022004451A2 (pt) 2022-06-21
US20210087189A1 (en) 2021-03-25
US20210087190A1 (en) 2021-03-25
US11548890B1 (en) 2023-01-10
EP4027995A1 (en) 2022-07-20
IL291244A (en) 2022-05-01
US11078201B2 (en) 2021-08-03
US20210078997A1 (en) 2021-03-18
WO2021050964A1 (en) 2021-03-18
US11034694B2 (en) 2021-06-15
CO2022002759A2 (es) 2022-06-21
CN114945366A (zh) 2022-08-26
US11028085B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).